In this issue:
Development and validation of a melanoma risk prediction model
Association of vitiligo with tumour response in patients with metastatic melanoma treated with pembrolizumab
Efficacy of anti-PD-1 agents in acral and mucosal melanoma
Outcomes in metastatic uveal
melanoma treated with PD-1 and PD-L1 antibodies
Arterial blood vs venous blood as a source for circulating melanoma cells
LPT + ipilimumab prolongs OS in patients with advanced malignant melanoma
Resection followed by adjuvant RT for patients with DM
Surgical management in adults with primary cutaneous melanoma at high risk of spread
Detection of invasive scalp melanoma
Outcome following discontinuation of BRAF inhibitor therapy after CR in metastatic melanoma
Please login below to download this issue (PDF)